| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| GYRE THERAPEUTICS, INC. | Chief Financial Officer | Stock Option (Right to Buy) | 50,000 | 07 Jan 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| GYRE | GYRE THERAPEUTICS, INC. | 07 Jan 2026 | 1 | $0 | 4 | Chief Financial Officer | 09 Jan 2026, 16:01 |
| GYRE | GYRE THERAPEUTICS, INC. | 14 Aug 2024 | 1 | $0 | 4 | Chief Financial Officer | 16 Aug 2024, 20:53 |
| GYRE | GYRE THERAPEUTICS, INC. | 20 Nov 2023 | 1 | $0 | 4 | Chief Financial Officer | 22 Nov 2023, 19:34 |
| GYRE | GYRE THERAPEUTICS, INC. | 31 Oct 2023 | 1 | $0 | 4 | Interim CFO | 01 Nov 2023, 06:15 |
| GYRE | GYRE THERAPEUTICS, INC. | 30 Oct 2023 | 0 | $0 | 3 | Interim CFO | 01 Nov 2023, 06:07 |